Resources for You and Your Patients

With the help of these resources, you can set up your patients and their care partners for success with VALTOCO® (diazepam nasal spray).

Tent

Get Free Training on How to Use VALTOCO

To help you and your staff understand how VALTOCO works and all it has to offer, start with a free Office Starter Kit that covers the following:

VALTOCO® starter kit

Usage of VALTOCO and administration training

Understanding the safety of VALTOCO

Prescribing VALTOCO—each kit comes with a prescription pad as well as information on e-prescribing through Maxor Specialty Pharmacy

Includes 2 demo devices

Get the Kit

Resources for Healthcare Providers

These downloadable resources can help guide your patients and their care partners on how to use VALTOCO, how to get their prescription fulfilled, and more.

VALTOCO patient brochure

Patient Brochure

This guide can help patients understand how to use VALTOCO, what individualized dosing looks like, and the programs available to them.

Get the Brochure

VALTOCO dosing card

Dosing Card

Read the full VALTOCO prescribing information.

Get It Here

VALTOCO frequently asked questions (FAQs)

Frequently Asked Questions

Get answers to common questions about VALTOCO.

Get the Document

VALTOCO full prescribing information

Prescription Form

VALTOCO is available to order through US retail pharmacies. To send your prescriptions through Maxor Specialty Pharmacy, use this form.

Get the Form

VALTOCO patient tip sheet

Patient Tip Sheet

This guide can help your patients learn how to get their VALTOCO prescription via Maxor Specialty Pharmacy.

Get the Sheet

VALTOCO office tip sheet

Office Tip Sheet

Help ensure your patients receive the VALTOCO you've prescribed by following the simple steps laid out in this document.

Get the Sheet

Resources for Pharmacists

Use the following information and tools to help you understand what you need to know to place orders of VALTOCO for your local pharmacy.

Wholesale guide for ordering VALTOCO

Dose NDC Number What's Included Pkg. Size /
Pkg. Quantity		 Box Dimensions /
Weight
5 mg 72252-505-02

This box contains two (2) individual blister packs.

Each blister pack contains 1 VALTOCO nasal spray device.

Each VALTOCO nasal spray device contains 5 mg diazepam in 0.1 mL solution.

The entire carton is to be dispensed as a unit.

 1 / 2 3.457” x 2.552” x 4.214” /
0.134 lb
10 mg 72252-510-02

This box contains two (2) individual blister packs.

Each blister pack contains 1 VALTOCO nasal spray device.

Each VALTOCO nasal spray device contains 10 mg diazepam in 0.1 mL solution.

The entire carton is to be dispensed as a unit.

 1 / 2 3.457” x 2.552” x 4.214” /
0.134 lb
15 mg 72252-515-04

This box contains two (2) individual blister packs.

Each blister pack contains 2 VALTOCO nasal spray devices.

Each VALTOCO nasal spray device contains 7.5 mg diazepam in 0.1 mL solution.
Use both nasal spray devices for a full 15 mg dose.

The entire carton is to be dispensed as a unit.

 1 / 2 3.457” x 2.552” x 4.214” /
0.163 lb
20 mg 72252-520-04

This box contains two (2) individual blister packs.

Each blister pack contains 2 VALTOCO nasal spray devices.

Each VALTOCO nasal spray device contains 10 mg diazepam in 0.1 mL solution.
Use both nasal spray devices for a full 20 mg dose.

The entire carton is to be dispensed as a unit.

 1 / 2 3.457” x 2.552” x 4.214” /
0.163 lb

Store at room temperature between 68°F and 77°F (20°C to 25°C). Do not freeze. Protect from light.1

VALTOCO trade sheet

Trade Sheet

Print out this trade sheet and keep it handy for when it's time to place orders of VALTOCO for patients.

Get the Trade Sheet

VALTOCO notice for pharmacists

Notice – Dear Health Care Provider Letter

Attention Pharmacists – View important prescribing information notice for VALTOCO: Correct dosing for 5 mg and 10 mg doses.

Get the Notice

Resources for School Nurses

It's not an easy task to keep track of all of your students' health needs, so we made it easier for you. Review the curated resources and tools you need to help students who have been prescribed VALTOCO.

VALTOCO school nurse FAQ

School Nurse Frequently Asked Questions

Review commonly asked questions about VALTOCO so that you'll be well versed on this rescue medication.

Get the Cheat Sheet

VALTOCO school nurse classroom confidence

VALTOCO: Confidence in the Classroom

Get acquainted with important information about VALTOCO, so that you'll be ready to help students who need it most.

Get the Resource

VALTOCO demo kit

Practice How to Give VALTOCO

Order a kit that includes a training device that will allow you to get a feel for how VALTOCO is administered. You’ll also get a quick start guide, medication guide, and more.

Interested in more than one demo device? Contact myNEURELIS™ for assistance at 1-866-myNEURELIS (1-866-696-3873). You can also contact myNEURELIS for virtual training on how to give VALTOCO.

Get the Demo Kit

more information on seizure treatment

Find out what myNEURELIS™ is and how it can provide savings and support to your patients, their care partners, and your staff.

Tailored to Patient Needs

IMPORTANT SAFETY INFORMATION,
INCLUDING BOXED WARNING

Down arrow

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
  • The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
  • The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

  • Hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome”, can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS

  • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
  • The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
  • The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Contraindications: VALTOCO is contraindicated in patients with:

  • Hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome”, can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

Reference: 1. VALTOCO® (diazepam nasal spray) Prescribing Information. Neurelis, Inc.